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Abstract
Background: Achieving ‘personalized medicine’ requires enrolling representative cohorts into genetic studies, but
patient self-selection may introduce bias. We sought to identify characteristics associated with genetic consent in a
myocardial infarction (MI) registry.
Methods: We assessed correlates of participation in the genetic sub-study of TRIUMPH, a prospective MI registry (n
= 4,340) from 24 US hospitals between April 2005 and December 2008. Factors examined included extensive socio-
demographics factors, clinical variables, and study site. Predictors of consent were identified using hierarchical
modified Poisson regression, adjusting for study site. Variation in consent rates across hospitals were quantified by
the median rate ratio (MRR).
Results: Most subjects consented to donation of their genetic material (n = 3,484; 80%). Participation rates varied
greatly between sites, from 40% to 100%. After adjustment for confounding factors, the MRR for hospital was 1.22
(95% confidence interval (CI) 1.11 to 1.29). The only patient-level factors associated with consent were race (RR 0.93
for African Americans versus whites, 95% CI 0.88 to 0.99) and body mass index (RR 1.03 for BMI ≥ 25, 95% CI 1.01
to 1.06).
Conclusion: Among patients with an MI there were notable differences in genetic consent by study site, but little
association with patient-level factors. This suggests that variation in the way information is presented during
recruitment, or other site factors, strongly influence patients’ decision to participate in genetic studies.
Background
As genetic research becomes more common and genetic
factors are studied as a means for improving risk stratifi-
cation and treatment, it is essential that participating
subjects are representative of the general population of
patients from which they are recruited. However, genetic
research often attains lower participation rates com-
pared with non-genetic studies [1]. Failure to recruit eli-
gible subjects may also introduce selection biases into
genetic studies, potentially jeopardizing both internal
and external validity. Existing studies addressing this
issue have revealed participation rates for genetic studies
ranging from 21% to 99% [2-5]. This variability depends
on many factors, including the disease under study [6],
circumstances in which the patient is recruited [5], as
well as a variety of patient characteristics that may
impact patients’ willingness to participate, including race
[7,8], education [9,10], and gender [3,7,8,11].
The existing literature has limited data regarding the
genetic participation of patients with acute illnesses,
which are required to study common cardiovascular dis-
eases such as myocardial infarction (MI). First, some of
the larger published studies are based upon opinion sur-
veys (that is, asking whether the subject would be will-
ing to participate in a theoretical genetic study)
[2,10,12]. While these are important to help illuminate
subjects’ decision-making processes, subjects considering
actual sample donation may behave differently when
faced with the reality of undergoing blood/tissue collec-
tion, the potential risk of a confidentiality breach, or
other real or perceived consequences of genetic analyses.
Among studies that did involve actual donation and
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patients enrolled during the course of acute illness,
which may also affect participation rates. For example,
dissimilar participation rates have been reported for
population-based studies compared to hospital-based
cohorts [5]. Further clouding the literature is that most
genetic studies have not adequately described popula-
tions from which samples were recruited, precluding an
assessment of participation bias and potentially affecting
internal and external validity [5]. The only study we are
aware of examining genetic participation rates in an MI
registry found significant clinical differences between
participants and non-participants [13], calling into ques-
tion the external validity of this study. A better under-
standing of the variability in patients’ willingness to
participate in genetic studies of acute cardiovascular dis-
ease is needed to assess for selection biases and to iden-
tify opportunities to improve participation and optimize
the generalizability of such studies.
To address this existing knowledge gap, we examined
characteristics associated with participation in a genetic
sub-study within a large multi-center registry of MI
patients. TRIUMPH (Translational Research Investigat-
ing disparities in Myocardial infarction Patients’ Health
status) is a multi-center study of MI patients at 24 US
centers spread across the country and representing
urban, suburban, academic, and community hospitals. A
principal goal of this study was to assess genetic and
pharmacogenomic factors associated with post-MI out-
comes. Each enrolled patient was invited, but not
required, to contribute DNA for genetic study. Partici-
pating hospitals were from diverse regions, including
academic and community centers, a broad spectrum of
economic and racial populations, as well as urban and
rural locations. As such, TRIUMPH provided an ideal
opportunity to examine patient factors associated with
participation in genetic studies. Specifically, we sought
to identify factors associated with genetic study partici-
pation, and to examine any differences between partici-
pants and those who chose not to donate their genetic
material, in the hopes that these insights could improve
recruitment in future studies.
Materials and methods
Participants
All data and analyses presented here are part of the
TRIUMPH study, a prospective registry of patients with
acute MI from 24 hospitals across the United States
(listed in Acknowledgements). The study was Institu-
tional Review Board approved at all participating sites,
and written informed consent was obtained from all
participants. All patients who entered the registry were
also offered participation in the genetic sub-study; how-
ever, this was not mandatory (that is, patients could
participate in the registry without contributing DNA). A
Federal Certificate of Confidentiality was obtained to
further protect the confidentiality of patients’ informa-
tion and this was disclosed to patients in the informed
consent document. Patients were enrolled from April
2005 to December 2008.
Data collection
For each patient in the parent study, detailed clinical
and treatment characteristics were collected by chart
abstraction and interview. Trained data collectors at
each site participated in the acquisition of requisite data.
Factors examined for association with genetic study par-
ticipation included the socio-demographic, financial,
social support, medical literacy, health status, depressive
symptoms, clinical variables listed in Table 1 and enroll-
ment site. All psychosocial and health status characteris-
tics were quantified using standardized instruments, as
previously described for the PREMIER study [14].
All study staff underwent similar training at in-person
meetings. Ongoing data collection issues were addressed
through monthly conference calls. There were similar
staffing ratios (per-recruited patient) across sites. Tem-
plates for informed consent documents and educational
pamphlets about the study were provided and used or
modified by each site.
Statistical analyses
Patients were divided into two groups based on whether
they consented to donate their genetic material (DNA)
for storage and study, or not. Patient characteristics
were compared using Chi-square tests for categorical
variables and t-tests for continuous ones. The likelihood
of consent was modeled using hierarchical regression
that included a random effect for hospital. Because the
consent rate was high, we estimated rate ratios (RRs)
directly (that is, instead of estimating odds ratios) by
using a modified Poisson regression model with robust
standard errors [15]. For multivariable models, we initi-
ally included characteristics thought a priori to be asso-
ciated with participating in the genetic sub-study. These
included age, race, gender, education, finances, social
support, symptom severity, and hospital. In order to
assess for potentially important patient characteristics,
we also included the characteristics from Table 1 that
showed univariate association with participation (P <
0.05) in the multivariable models. Variation in consent
rates between hospitals was quantified by the median
rate ratio (MRR), which estimates the average relative
difference in likelihood of two hypothetical patients,
with identical covariates, consenting if enrolled at two
different hospitals. Site participation rates are shown as
smoothed estimates, which are a weighted average of
the hospital’s individual rate and the overall rate for the
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Consented to use of DNA
Yes (n = 3,484) No (n = 856) P-value
Demographics
Age 58.9 ± 12.2 59.8 ± 12.7 0.038
White/Caucasian race 2,342 (67.4%) 573 (67.3%) 0.981
Male 2,347 (67.4%) 551 (64.4) 0.095
Language 0.293
English 3,353 (98.4%) 823 (97.9%)
Spanish 55 (1.6%) 18 (2.1%)
Missing 76 15
Ethnicity 0.870
Hispanic/latino 217 (6.4%) 54 (6.6%)
Non-hispanic/latino 3,175 (93.6%) 770 (93.4%)
Unknown 92 32
Low social support 612 (18.3%) 109 (13.1%) < 0.001
Missing 133 23
REALM-R score ≤ 6 844 (28.5%) 170 (28.1%) 0.823
NA, missing, or unknown 423 250
Socio-economic status
Completed high school 2,764 (79.8%) 656 (76.9%) 0.058
History of avoiding medical care due to cost 904 (26.5%) 184 (21.7%) 0.004
End-of-month financial situation <0.001
Some money left over 1,380 (40.4%) 397 (47.3%)
Just enough to make ends meet 1,297 (37.9%) 295 (35.1%)
Not enough to make ends meet 741 (21.7%) 148 (17.6%)
Medical history
BMI 29.8 ± 10.2 29.0 ± 6.5 0.025
Chronic heart failure 302 (8.7%) 70 (8.2%) 0.646
Dyslipidemia 1,721 (49.4%) 407 (47.5%) 0.332
Hypertension 2,318 (66.5%) 575 (67.2%) 0.722
Prior MI 710 (20.4%) 202 (23.6%) 0.038
Cancer 250 (7.2%) 62 (7.2%) 0.946
Diabetes 1,068 (30.7%) 268 (31.3%) 0.710
Presentation
Final MI diagnosis 0.568
STEMI 1,475 (42.3%) 383 (44.7%)
NSTEMI 1,979 (56.8%) 465 (54.3%)
BBB/uncertain type 7 (0.2%) 2 (0.2%)
Patient not diagnosed with MI 23 (0.7%) 6 (0.7%)
Peak troponin 29.3 ± 76.6 25.6 ± 58.1 0.187
Medications (arrival and discharge)
Aspirin on arrival 1,431 (41.1%) 353 (41.2%) 0.930
Beta blocker at DC 3,109 (89.7%) 776 (91.4%) 0.132
Thienopyridine on Arrival 433 (12.4%) 113 (13.2%) 0.541
Statin at DC 3,030 (87.4%) 744 (87.6%) 0.852
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hospital is roughly proportional to their sample size.
Smoothing was used in order to take into account the
fact that some hospitals have small sample sizes and
thus more uncertainty around their true rate.
Approximately 16.1% of patients had missing covariate
data (13.8% were missing one value, 1.8% were missing
two values, and 0.5% were missing three or more values;
the highest missing rate for any single variable (Patient
Health Questionnaire (PHQ) depression score) was
6.4%. Missing covariate data were imputed with multiple
imputation using IVEwareE [16]. All analyses were per-
formed in SAS version 9.1.3 (SAS Institute, Cary, North
Carolina, USA), and R, version 2.7.0 (Foundation for
Statistical Computing, Vienna, Austria).
Results
A total of 4,340 patients were enrolled in the study. Of
these, 3,484 (80%) consented to donate their DNA for
study. Clinical and socio-demographic characteristics
among genetic sub-study participants versus non-partici-
pants are summarized in Table 1. Several socio-demo-
graphic factors differed between participants and non-
participants in unadjusted analyses, including measures
of social support, literacy, education, financial hardship,
and smoking status. Among clinical variables, health
status, body mass index (BMI), history of MI, history of
stroke, and receiving beta-blockers on arrival each had
univariate associations with genetic consent. The genetic
participation rate varied across enrolling sites, ranging
from 40% to 100%. Smoothed estimates of site participa-
tion rates derived from the random effects model are
shown in Figure 1.
A multivariable modified Poisson model was then
constructed to test for factors associated with consent-
ing to genetic testing (Figure 2). The only factors inde-
pendently associated with participation were African
American race, enrollment site, and BMI. African Amer-
ican race was associated with a 7% lower rate of con-
senting to genetic study compared with white patients
(RR 0.93; 95% confidence interval (CI) 0.88 to 0.99).
Higher BMI (≥ 25) was marginally associated with a
slightly higher participation with RR of 1.03 (95% CI
1.01 to 1.06). Several other factors were of borderline
significance, including PHQ-9 score (RR 1.02 for every 5
points; 95% CI 1.00 to 1.05) and chronic lung disease
(RR 1.04; 95% CI 1.00 to 1.08). By far, the strongest fac-
tor associated with participating in the genetic study
was enrollment site. The MRR was 1.22 (95% CI 1.11 to
1.29), suggesting that an identical patient presenting at
o n eh o s p i t a lw o u l d ,o na v e r a g e ,h a v ean e a r l y1i n4
greater likelihood of participating in a genetic study
Table 1 Patient characteristics in genetic sub-study participants versus non-participants (Continued)
Processes of care
In-hospital cardiac catheterization 3,222 (92.5%) 777 (90.8%) 0.096
In-hospital revascularization 2,498 (71.7%) 618 (72.2%) 0.772
Enrolled in other study 326 (9.4%) 70 (8.2%) 0.283
Length of stay 5.6 ± 6.4 6.0 ± 8.90 0.207
Health Status
SAQ Quality of Life score 62.2 ± 23.6 67.5 ± 23.3 < 0.001
SAQ Angina Stability score 43.8 ± 21.8 47.1 ± 20.6 < 0.001
SAQ Physical Limitation score 85.0 ± 22.6 88.4 ± 19.6 < 0.001
SF-12v2 Mental Component score 49.6 ± 11.5 50.0 ± 11.6 0.411
SF-12v2 Physical Component score 42.0 ± 12.4 42.8 ± 12.5 0.094
PHQ-9 depression severity <0.001
Not clinically depressed 1,763 (54.4%) 539 (65.7%)
Mild depression 831 (25.6%) 170 (20.7%)
Moderate depression 376 (11.6%) 72 (8.8%)
Moderately severe depression 191 (5.9%) 27 (3.3%)
Severe depression 81 (2.5%) 12 (1.5%)
Missing 242 36
GRACE 6 m Mortality Risk score 100.0 ± 29.81 103.0 ± 31.1 0.008
Baseline patient characteristics are listed in the left-most column, with the quantities for those that participated in the genetic study, those that did not, and the
P-value for difference between the two in the subsequent three columns. Categorical variables are shown as the number of subjects with that characteristic,
followed by the proportion this represents (percentage) in parentheses. For variables that have subcategories, each subcategory and the number and proportion
of subjects in that group is shown. Continuous variables are shown as the mean ± the standard deviation. Categorical variables were compared using chi-square
or Fisher’s exact test. Continuous variables were compared using Student’s t-test. BBB, bundle branch block; BMI, body mass index; DC,; GRACE, Global Registry of
Acute Coronary Events; NA, not applicable; NSTEMI, non-ST elevation myocardial infarction; PHQ, Patient Health Questionnaire; SAQ, Seattle Angina Questionaire;
SF, Short Form; STEMI, ST elevation myocardial infarction.
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TRIUMPH hospital.
Discussion
We sought to define characteristics associated with par-
ticipation in a genetic sub-study of a large acute MI reg-
istry. We found that the vast majority of patients chose
to participate in genetic testing (around 80%), with few
differences between those who did and did not agree to
donate DNA. Although we found race to be mildly asso-
ciated with patients’ willingness to participate in genetic
studies, other factors such as gender and education level
were not. Most importantly, the strongest predictor of
participation in the genetic sub-study was hospital site,
with wide variability seen in rates across sites.
Reduced genetic participation among racial minorities
is a particularly critical issue since racial disparities in
health outcomes are high-priority research topics, and
the genetic versus non-genetic components of health
disparities need to be better elucidated. Higher rates of
participation in genetic studies among white patients, as
compared with African Americans, have been previously
described [4,7,8]. A lower likelihood of African
American participation in medical research generally
has also been well described, with lack of trust or confi-
dence in the researchers being one important factor
[17]. Similarly, trust is one of the most often cited med-
iating factors for participation in genetic studies [2], and
this is also the case in studies specifically focusing upon
racial differences in genetic research; patient concerns
about confidentiality were a consistent reason for choos-
ing not to participate [12,18]. In our study, African
Americans were 7% less likely to participate than whites,
a modest difference in participation rates. While further
qualitative studies may help illuminate the mechanism,
awareness of this potential selection bias is important
during study enrollment so that under-representation of
racial minorities can be minimized. Making every effort
to establish trust and rapport with subjects, as well as
confidence in the research team and their confidentiality
protections, may help reduce refusal rates.
To our knowledge, the association of genetic consent
with BMI has not been previously reported, and the
magnitude of the association is of questionable clinical
significance. Given the number of possible predictors
included in this study, this association may be spurious.
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proportion of subjects at the site that consented to genetic sub-study enrollment. The central dot shows the point estimate of the site rate
(percentage) generated from the random effects models. The lines extending from the dot represent the 95% confidence interval.
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needed and, if consistent findings are observed, then
qualitative research could be used to better understand
the potential mechanism of this association. In contrast
to previous studies, our data did not show any other
patient level characteristics to be significantly associated
with patients’ willingness to consent to genetic testing.
Some additional aspects of our data are worth noting.
First, our study examined acutely ill hospitalized
patients, while most previous studies were outpatient or
population-based. We found rates of participation
roughly similar to previous studies of patients that had
already consented to non-genetic research [4,19,20]. The
only other published genetic MI registry addressing par-
ticipation rates [13], identified clinical selection biases,
but these were not confirmed in ours. In contrast, our
data demonstrated that patients consenting to genetic
participation were overall quite similar to those who
chose not to participate across a wide range of clinical
factors. This difference may be due to the fact that ours
is a multi-center cohort, as opposed to the single-center
experience of the previous study. Given the importance
of recruitment site in our study, there may have been
unique characteristics of that site that influenced their
findings. Nevertheless, it is critically important that
genetic association studies ex p l i c i t l yq u a n t i f yp o t e n t i a l
selection biases of the participating cohort compared
with the parent population to whom the conclusions
will be applied. The similarity of our genetic versus
non-genetic patients supports the external validity of the
future genetic analyses planned for these data.
Most importantly, we were able to clearly identify that
site of recruitment was the most important factor asso-
ciated with participation. While the mechanism can not
be stated with certainty, this most likely reflects varia-
tions between centers in the presentation style of indivi-
dual study coordinators, their motivation to recruit into
the genetic study, ability to establish rapport and trust,
or their ability to provide complete information to
patients’ satisfaction and comfort. If this is true, the
marked variation across sites indicates an important
opportunity, through better training and standardization,
to improve enrollment processes in future studies.
Ensuring high-quality and consistent consent processes
should reduce variability inc o n s e n tr a t e sa n dm a ya l s o
provide overall enhanced participation in genetic asso-
ciation studies. This is highly desirable in order to mini-
mize the potential for bias and enhance generalizability.
Although specific training regarding genetic enrollment
was done at the beginning of our study, changes in
study coordinators and shifts in their responsibilities
may have limited the effectiveness of the initial standar-
dization for DNA acquisition across sites. Moreover,
testing, through role-playing, coordinators’ skills in
obtaining informed consent are important steps for
future studies to consider. We further suggest that
future studies provide ongoing assessments of the rates
of genetic consents at each center to rapidly identify
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Figure 2 Multivariable model of participation in genetic sub-study. Variables included in the model are shown along the vertical axis. The
strength of effect is shown along the horizontal axis with the vertical dotted line demarking a rate ratio of 1 (that is, no effect); estimates to the
right (that is, > 1) are associated with greater likelihood of genetic consent while those to the left (that is, < 1) indicate association with reduced
likelihood of genetic consent. Each dot and line represents the point estimate of the effect of that variable in the model, while the line shows
the 95% confidence interval. CVA, Cerebral Vascular Accident; HCT, hematocrit; PHQ, Patient Health Questionnaire; SF-12 PCS, short form 12
physical component score.
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proactive education of site coordinators can occur
throughout the study. These data also underscore the
importance of close collaborations between investigators,
coordinators, Institutional Review Boards and others
involved in genetic studies to optimize communication
with subjects, assess their comprehension, and to pro-
vide strong protections (for example, confidentiality)
that can maximize patient comfort with, and participa-
tion in, genetic research.
Our findings should be interpreted in the context of
the following potential limitations. First, we can not
completely exclude the possibility that unidentified
variation in patient characteristics between sites may
have led to residual confounding of the observed dif-
ferences in participation rates. Specifically, there could
theoretically be regional differences in patient attitudes
towards genetic study that influence participation deci-
sions that were not quantifiable from our extensive
data collection, given that geographic region and
enrollment site are highly correlated. Second, our data
do not identify the mechanism underlying our
observed associations, which would require additional
qualitative studies to better understand determinants
of patient decision-making.
Conclusions
Our multi-center study was able to engage 80% of
patients to participate in genetic research at the time of
their acute MI. Genetic participants were clinically simi-
lar to those who chose not to donate their genetic mate-
rial. African American patients, as compared with white
patients, had a slightly lower rate of genetic participa-
tion, but no other patient-level factors, including gender
and education, were significantly associated with con-
sent. While BMI was statistically associated with partici-
pation rates, the magnitude of the effect was small and
this association has not been previously observed to our
knowledge. Most importantly, the strongest factor asso-
ciated with genetic consent was enrollment site. This
suggests that differences in how study personnel interact
with patients are a key determinant of their willingness
to participate, and should be prospectively monitored in
future studies to maximize participation rates in genetic
investigations.
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